{"log_id": 1400349752065404674, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 5.2e-05, "average": 0.997049, "min": 0.966748}, "location": {"width": 848, "top": 211, "height": 36, "left": 184}, "words": "线的时候进行心电图、MUGA扫描或者ECHO检查,这尤其适合于那些具有高危风险因素的患者。应反复"}, {"probability": {"variance": 0.001944, "average": 0.986591, "min": 0.732466}, "location": {"width": 849, "top": 250, "height": 37, "left": 184}, "words": "进行MUGA扫描或ECHO检查以评估左室射血分数,尤其是在使用高累积剂量蒽环类药物时。整个随访"}, {"probability": {"variance": 1e-06, "average": 0.999216, "min": 0.995831}, "location": {"width": 270, "top": 296, "height": 29, "left": 185}, "words": "期间用于评估的技术要保持一致"}, {"probability": {"variance": 1.2e-05, "average": 0.998433, "min": 0.978274}, "location": {"width": 810, "top": 330, "height": 36, "left": 223}, "words": "发生心脏毒性的危险因素包括活动性或非活动性的心血管疾病、目前或既往接受过纵膈/心脏周围"}, {"probability": {"variance": 0.000199, "average": 0.997048, "min": 0.905143}, "location": {"width": 849, "top": 369, "height": 37, "left": 185}, "words": "区域的放射治疗,之前用过其他蒽环类药物或者蒽二酮药物、同时使用其他抑制心肌收缩功能的药物"}, {"probability": {"variance": 9.8e-05, "average": 0.996977, "min": 0.951283}, "location": {"width": 848, "top": 409, "height": 35, "left": 186}, "words": "或者具有心脏毒性的药物(例如曲妥珠单抗)。除非患者的心功能得到严密的监测,否则蒽环类药物包"}, {"probability": {"variance": 3e-06, "average": 0.999056, "min": 0.988724}, "location": {"width": 847, "top": 447, "height": 37, "left": 186}, "words": "括伊达比星不能与其他具有心脏毒性的药物同时使用。患者在停止使用其他具有心脏毒性的药物(特"}, {"probability": {"variance": 4.1e-05, "average": 0.997556, "min": 0.960884}, "location": {"width": 836, "top": 486, "height": 34, "left": 186}, "words": "别是具有长半衰期的药物例如曲妥珠单抗)之后接受蒽环类药物,也可能会增加发生心脏毒性的风险"}, {"probability": {"variance": 7e-06, "average": 0.998933, "min": 0.986383}, "location": {"width": 846, "top": 524, "height": 34, "left": 187}, "words": "曲妥珠单抗的半衰期约为28.5天并且在血循环中可以持续至24周。因此,如果可能,医师应该在停"}, {"probability": {"variance": 0.003542, "average": 0.98971, "min": 0.595165}, "location": {"width": 849, "top": 561, "height": 36, "left": 185}, "words": "用曲妥珠单抗之后的24周内避免使用以蒽环类药物为基础的治疗。但是,如果要在这段时间内使用蒽"}, {"probability": {"variance": 0.000143, "average": 0.996254, "min": 0.926524}, "location": {"width": 846, "top": 600, "height": 34, "left": 187}, "words": "环类药物,须密切监测心脏功能。对接受高累积剂量伊达比星及具有高危风险的患者应进行严格的心"}, {"probability": {"variance": 1e-06, "average": 0.999173, "min": 0.995726}, "location": {"width": 806, "top": 638, "height": 33, "left": 185}, "words": "脏功能的监测。然而无论是否存在心脏毒性危险因素,在累积剂量较低时仍有可能发生心脏毒性"}, {"probability": {"variance": 2e-06, "average": 0.99914, "min": 0.993035}, "location": {"width": 745, "top": 678, "height": 34, "left": 227}, "words": "婴儿和儿童似乎对伊达比星诱发的心脏毒性更加易感,必须长期进行定期的心脏功能评估"}, {"probability": {"variance": 0.000234, "average": 0.996168, "min": 0.915553}, "location": {"width": 556, "top": 721, "height": 30, "left": 228}, "words": "伊达比星和其他蒽环类或蒽二酮类药物的毒性作用可能具有累积性"}, {"probability": {"variance": 1e-06, "average": 0.999152, "min": 0.997668}, "location": {"width": 80, "top": 807, "height": 25, "left": 189}, "words": "血液毒性"}, {"probability": {"variance": 1e-05, "average": 0.998621, "min": 0.981333}, "location": {"width": 729, "top": 840, "height": 31, "left": 228}, "words": "伊达比星是强烈的骨髓抑制剂。所有患者使用治疗剂量的本品都会出现严重的骨髓抑制"}, {"probability": {"variance": 0.000149, "average": 0.996038, "min": 0.925305}, "location": {"width": 806, "top": 878, "height": 33, "left": 229}, "words": "使用伊达比星前及每个周期中都应进行血液学检查,包括白细胞(WBC)计数。剂量依赖性的、可"}, {"probability": {"variance": 0.001904, "average": 0.991863, "min": 0.703322}, "location": {"width": 847, "top": 917, "height": 32, "left": 189}, "words": "逆的白细胞减少和/或粒细胞减少(中性粒细胞减少为主)是伊达比星主要的血液学毒性,并且是伊达"}, {"probability": {"variance": 5e-06, "average": 0.998656, "min": 0.988921}, "location": {"width": 845, "top": 955, "height": 33, "left": 190}, "words": "比星最常见的急性剂量限制性毒性。白细胞减少或中性粒细胞减少通常很严重,血小板减少和贫血也"}, {"probability": {"variance": 1.3e-05, "average": 0.998421, "min": 0.982036}, "location": {"width": 848, "top": 994, "height": 33, "left": 191}, "words": "有可能发生。中性粒细胞和血小板计数一般在用药后的10至14天达到最低点,但大部分患者的细胞"}, {"probability": {"variance": 0.00292, "average": 0.988808, "min": 0.638056}, "location": {"width": 848, "top": 1030, "height": 36, "left": 189}, "words": "计数会在第3周内恢复至正常范围。严重骨髓抑制的临床表现包括发热、感染、脓毒血症/败血症、感"}, {"probability": {"variance": 0.000101, "average": 0.99628, "min": 0.957519}, "location": {"width": 328, "top": 1075, "height": 28, "left": 191}, "words": "染性休克、出血、组织缺氧、甚至死亡"}, {"probability": {"variance": 0.060821, "average": 0.710264, "min": 0.396}, "location": {"width": 109, "top": 1099, "height": 56, "left": 854}, "words": "药分"}, {"probability": {"variance": 0.001006, "average": 0.976852, "min": 0.927785}, "location": {"width": 118, "top": 1158, "height": 25, "left": 191}, "words": "继发性白血病"}, {"probability": {"variance": 0.000447, "average": 0.995189, "min": 0.86105}, "location": {"width": 805, "top": 1188, "height": 36, "left": 230}, "words": "有报道在使用蒽环类药物包括伊达比星的患者中出现了继发性白血病,可伴或不伴白血病前期症"}, {"probability": {"variance": 1.6e-05, "average": 0.99851, "min": 0.974041}, "location": {"width": 830, "top": 1226, "height": 37, "left": 191}, "words": "状。下列情况下出现继发性白血病更为常见:当与作用机制为破坏DNA结构的抗癌药物联合使用时"}, {"probability": {"variance": 0.002405, "average": 0.990465, "min": 0.67449}, "location": {"width": 813, "top": 1267, "height": 34, "left": 192}, "words": "或患者既往多次使用细胞毒药物时,或者蒽环类药物治疗剂量加量时。此类白血病的潜伏期通常为"}, {"probability": {"variance": 0, "average": 0.999918, "min": 0.999867}, "location": {"width": 34, "top": 1315, "height": 20, "left": 192}, "words": "3年"}, {"probability": {"variance": 1e-06, "average": 0.998513, "min": 0.997661}, "location": {"width": 61, "top": 1394, "height": 25, "left": 193}, "words": "胃肠道"}, {"probability": {"variance": 2.3e-05, "average": 0.998057, "min": 0.97142}, "location": {"width": 789, "top": 1424, "height": 34, "left": 233}, "words": "伊达比星会引起呕吐反应。粘膜炎(主要是口腔炎,食管炎少见)通常会发生在给药后的早期"}, {"probability": {"variance": 0.019931, "average": 0.940966, "min": 0.59518}, "location": {"width": 126, "top": 1531, "height": 23, "left": 557}, "words": "第6页,共1页"}, {"probability": {"variance": 0.005042, "average": 0.959455, "min": 0.792913}, "location": {"width": 61, "top": 1561, "height": 18, "left": 264}, "words": "2011020"}], "language": 3}